T-cell therapy for EBV-associated nasopharyngeal carcinoma : preparative lymphodepleting chemotherapy does not improve clinical results by S. Secondino et al.
Annals of Oncology
doi:10.1093/annonc/mdr134original article
T-cell therapy for EBV-associated nasopharyngeal
carcinoma: preparative lymphodepleting chemotherapy
does not improve clinical results
S. Secondino1, M. Zecca2, L. Licitra3, A. Gurrado2, I. Schiavetto1, P. Bossi3, L. Locati3,
R. Schiavo1, S. Basso2, F. Baldanti4, R. Maccario2, F. Locatelli2, S. Siena1, P. Pedrazzoli1 &
P. Comoli2*
1Falck Medical Oncology, Niguarda Ca’ Granda Hospital, Milano; 2Pediatric Hematology/Oncology and Research Laboratories, Fondazione IRCCS Policlinico San
Matteo, Pavia; 3Head and Neck Medical Oncology Unit, Fondazione IRCCS ‘Istituto Nazionale dei Tumori’, Milano; 4Virology Service, Fondazione IRCCS Policlinico
San Matteo, Pavia, Italy
Received 10 November 2010; revised 5 January 2011; revised 21 January 2011; accepted 7 March 2011
Background: We and others have demonstrated that adoptive cell therapy with Epstein–Barr virus (EBV)-specific
autologous cytotoxic T lymphocytes (CTLs) may control disease progression in patients with EBV-associated
nasopharyngeal carcinoma (NPC). With the aim of favoring in vivo T-cell expansion, we optimized our cell therapy
approach by administering higher doses of EBV-specific CTLs, following lymphodepleting chemotherapy.
Patients and methods: Eleven patients with EBV-related NPC in whom conventional treatment failed have been
enrolled. Patients received nonmyeloablative lymphodepleting chemotherapy consisting of cyclophosphamide and
fludarabine. Two doses of autologous EBV-specific CTLs were subsequently infused, 2 weeks apart. Study end points
were feasibility and clinical outcome.
Results: All patients enrolled completed the treatment and were assessable for analysis. The median dose of CTLs
per infusion was 3.7 · 108. Therapy was well tolerated, with no severe adverse events ascribable to either
chemotherapy or cell therapy. Disease control (defined as either tumor regression or disease stabilization lasting >4
months) was obtained in 6 of 11 patients, in keeping with previously published results.
Conclusions: Our data confirm that EBV-specific CTL therapy is safe and associated with antitumor activity in
patients with advanced NPC. The use of lymphodepleting chemotherapy before high-dose CTL infusion did not
enhance the clinical benefit observed in our previous series.
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introduction
Nasopharyngeal carcinoma (NPC) is a squamous epithelium
neoplasm, characterized by marked differences in geographic
and population incidence. Although NPC is seen worldwide, it
is most common throughout Southeast Asia, where the
frequency is as high as 50 per 100 000 [1]. In Europe, it is rarely
observed, with an incidence ranging between 0.1 and 22 per
100 000 [2]. State-of-the-art treatment strategies for locally
advanced NPC consist mainly in radiotherapy alone or in
combination with platinum-based chemotherapy [3] and yield
an overall response rate of 90%, with substantial cure rates [4,
5]. Induction treatment is able to improve disease-free survival,
while its impact on survival still needs to be demonstrated. In
local–regional recurrent NPC not amenable to re-irradiation,
combination platinum-based chemotherapy is the standard
first-line treatment, with response rates reaching 40%–80%,
mainly depending on previous treatment and duration of the
disease-free interval [6, 7]. Combination platinum-based
chemotherapy is standard therapy also in patients presenting
with metastatic disease [6, 7]. Second-line therapies in patients
refractory to platinum-based regimens may also lead to clinical
benefit [8–10], which is generally short-lived, although long-
term surviving patients with metastatic disease treated with
chemotherapy and radiotherapy have been reported [11].
Overall, this finding supports the development of additional
forms of treatment of NPC.
NPC is consistently associated with the Epstein–Barr virus
(EBV). Within the tumor, viral infection is latent with
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expression of the EBV proteins latent membrane proteins
(LMP)-1, LMP2, Epstein–Barr virus nuclear antigen-1 (EBNA1)
and Epstein–Barr virus-encoded small RNA (EBER) and BamHI
A RNAs [12]. The continued expression of multiple viral
proteins on malignant cells provides an opportunity to target
viral proteins using virus-directed cellular therapy. In support of
this concept, clinical studies have demonstrated how infusion
of EBV-specific cytotoxic T lymphocytes (CTLs) expanded
in vitro could safely and effectively either prevent or treat
EBV-positive lymphoproliferative disease occurring in bone
marrow or solid-organ transplant recipients [13–16].
Based on these premises, two independent pilot studies have
been conducted in the context of EBV-related NPC. The
published results demonstrated that clinical and immunological
responses could be obtained in some patients with
radiotherapy- and chemotherapy-resistant, stage IV, EBV-
related NPC through the administration of EBV-specific
autologous polyclonal CTL therapy [17, 18]. In an attempt to
further improve outcome in NPC patients treated with
adoptive cell therapy, we have modified our previously
published protocol [18] by administering higher doses of EBV-
polyspecific CTLs following a lymphodepleting
chemotherapeutic conditioning regimen.
patients and methods
patients
Eligible patients were <70 years of age with histologically confirmed, stage
IV, EBV-LMP1- and/or EBER-positive NPC. For enrollment, patients were
required to demonstrate documented disease progression by computed
tomography (CT) and/or magnetic resonance imaging (MRI), not
amenable to further systemic or local conventional treatments. Patients
were required to have normal organ function, while they were excluded if
undergoing immunosuppressive therapy or in the case of active brain
metastases. None of the patients received cytotoxic therapies within 30 days
of T-cell therapy.
Approval was obtained from the institutional review board. Patients gave
written informed consent before enrollment.
generation and characterization of EBV-specific CTLs
EBV-specific CTLs were prepared according to a previously described
procedure [19]. Peripheral blood mononuclear cells (PBMCs) and
autologous plasma were collected from all patients through a single
leukopheresis, collected at diagnosis or at disease relapse, before
chemotherapy/radiotherapy administration. EBV-specific CTLs were
expanded in vitro following good laboratory practice standard procedures.
Before cryopreservation, T cells were examined for EBV specificity in
a standard Cr 51-release assay against a panel of targets, including an
autologous B-lymphoblastoid cell line (LCL) and autologous
phytohemagglutinin (PHA) blasts pulsed with 2 lg/ml of a peptide mix
containing 15-mer peptides spanning the EBV-LMP2 protein (Jerini,
Berlin, Germany) or with control peptide. Lysis against allogeneic PHA
blasts was also tested. In addition, CTLs were analyzed for sterility and for
immunophenotype on a FACScan flow cytometer (Becton Dickinson,
Mountain View, CA) by direct cytofluorimetry employing the mAbs CD3
(anti-Leu-4) fluorescein isothiocyanate (FITC), anti-HLA-DR phycerythrin
(PE), CD8 (anti-Leu-2a) FITC and PE, CD56 (anti-Leu-19) PE, CD4 (anti-
Leu-3a) PE, CD19 (anti-Leu-12) FITC, and CD45 (anti-HLe-1) FITC
(Becton Dickinson).
EBV-specific CTL infusion schedule and patient
evaluation
The lymphodepletion treatment consisted in 4 days of consecutive
nonmyeloablative chemotherapy: cyclophosphamide (30 mg/kg daily) on
days 1–2 and fludarabine (30 mg/m2 daily) for 4 days. The fludarabine dose
was adjusted according to renal function. When profound lymphopenia
was achieved (i.e. an absolute lymphocyte count <0.2 · 109/l),
cryopreserved CTLs were thawed and administered i.v.; a second infusion
was carried out 2 weeks later. The median CTL dose was 3.7 · 108 (range
1.6–5); this infusion scheme was derived from our previous phase I study,
in which administration of lower doses of autologous EBV-specific CTLs
was demonstrated to be safe and feasible [18]. After the first infusion, all
patients also received low-dose recombinant interleukin 2 (IL-2) ; 1 · 106 U
s.c. daily for 3 weeks) in order to prolong in vivo T-lymphocyte life span.
Patients were monitored for evidence of toxicity by physical examination,
serum chemistry and daily complete and differential blood counts. Patient
response was assessed using standard radiographic studies (CT scan, MRI of
measurable lesions), physical examination and blood tests at baseline, 4
weeks following the second CTL administration and at regular 2-month
intervals thereafter. Radiographic response was defined according to
RECIST [20]. EBV DNA levels were monitored by PCR [21] on plasma
samples at baseline, after each CTL infusion, and every 2 months thereafter.
To evaluate the effects of CTL administration on the frequency of
interferon-c (IFN)-c-secreting lymphocytes and on EBV-directed cytotoxic
activity, patient peripheral blood samples were collected at baseline and at
different times after CTL infusions.
enzyme-linked immunospot assay
For the enzyme-linked immunospot (ELISPOT) assay, a previously
reported method was employed [18]. Briefly, 96-well multiscreen filter
plates (MAIPS 4510; Millipore, Bedford, MA) were coated with 100 ll of
primary antibody (IFN-c; Mabtech, Nacka, Sweden) at 2.5 lg/ml and
incubated overnight at 4C. PBMCs were thawed and cultured overnight in
RPMI medium with 10% fetal calf serum before use in the assay and were
then seeded in the presence of EBV-LCL or 2 lg/ml of the EBV-LMP2
peptide mix. After incubating for 24 h at 37C, 100 ll of the biotinylated
secondary antibody (0.5 lg/ml; Mabtech) was added, and plates were then
processed according to a standard procedure. IFN-c-producing spots were
counted using an Elispot reader (Bioline, Torino, Italy). The number of
spots per well was calculated after subtracting assay background, quantified
as an average of 24 wells containing only sterile complete medium, and
specific background, quantified as the sum of cytokine spots associated with
responders alone, LCL alone, or responders plated with dimethyl sulfoxide
solvent control, as appropriate.
results
patients and EBV-specific CTL line
characterization
Eleven consecutive patients received the treatment according to
the schedule described; all had histologically confirmed, EBV-
positive undifferentiated NPC. Relevant patient characteristics
are reported in Table 1.
EBV-specific CTL lines were successfully generated ex vivo
from all patients. Growth kinetics of the T-cell lines from this
cohort of NPC patients with disease progression was
comparable with those previously observed [18]. Phenotypic
analysis indicated that the CTL lines generated from PBMCs of
NPC patients were heterogeneous with respect to the
percentages of CD3+/CD8+ and CD3+/CD4+ cells. In detail,
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CD8+ cells ranged from 31% to 91% (median 88%), CD4+
lymphocytes ranged from 3% to 69% (median 9%), and the
CD3+/HLA-DR+ population was between 49% and 96%
(median 76%). Moreover, the CTL lines contained a median of
26% cells that were CD3+/CD8+/CD56+ and 4% cells with the
natural killer cell phenotype (CD56+/CD32).
The CTL lines were specific for EBV since they exerted
cytotoxicity toward autologous LCL (median percentage lysis at
an effector-to-target ratio of 10 : 1 : 64). Activity of EBV-CTL
lines against the LMP2 protein was present in 6 of the 11 patients
(median percentage lysis for the six CTL lines at an effector-to-
target ratio of 10 : 1, after subtracting control lysis: 16%, range
9–27). No lysis against allogeneic PHA blasts was observed.
toxicity profile of lymphodepletion followed by
EBV-targeted CTL therapy
Patients enrolled in the study received the nonmyeloablative
lymphodepleting chemotherapy and the first CTL infusion
during an hospital stay, while the second CTL infusion was
carried out on an outpatient basis. All patients were monitored
for immediate adverse reactions. No grade IV hematological
toxic effects were reported. Four patients developed grade III
neutropenia and received antimicrobial prophylaxis until
resolution. No episodes of grade III thrombocytopenia were
observed, while grade II thrombocytopenia and grade II anemia
were reported in two patients and one patient, respectively, not
requiring blood transfusions. Regarding non-hematological
side-effects of the lymphodepleting chemotherapy, no grade III
or IV toxic effects were observed, while mild toxic effects such as
fatigue and nausea occurred in six patients. Only one patient had
a systemic reaction immediately after the second CTL infusion,
with fever and tremors requiring antihistamine therapy.
Two patients (patient 2 and patient 7) developed swelling at
a disease site a few days after CTL infusion. Patient 7 developed
a severe inflammatory reaction at the orbital region, with visual
field defects, which was treated with antiinflammatory therapy,
including steroids. Patient 2 had a mild inflammatory reaction,
consisting of orbital edema, which resolved spontaneously.
Both side-effects are likely ascribable to tumor cell lysis. No
other adverse events ascribable to the CTL therapy were
observed in the remaining patients
lymphocyte kinetics after lymphodepletion
followed by EBV-targeted CTL therapy
The lymphodepletion regimen employed in our patients
profoundly decreased lymphocyte counts (Figure 1). At the first
Table 1. Main characteristics and clinical outcome of patients with NPC in progression after conventional therapy and treatment with EBV-specific
autologous CTLs
Patients
(UPN)
Age
(years)
Sex Stage at
diagnosis
Site(s) of tumor
involvement at the
time of cell therapy
Prior therapies ECOG
PS
Adverse
events
Best
response
(duration)
1 19 F IV (T4N2M0) Liver, spleen RT, three lines
of CT
0 None SD (4 months)
2 65 M III (T3N1M0) Primary tumor,
skull base
Two lines of
CT, RT,
surgery
0 Inflammatory
reaction at the
disease site; fever
and tremors
after second
infusion
PR (8 months)
3 21 M III (T3N1M0) Primary tumor,
skull base
Two lines of
CT, RT
0 None PD
4 40 F III (T2N2M0) Skull base, neck Three lines of
CT, RT
1 None SD (8 months)
5 48 M IV (T2N2M1) Primary tumor,
skull base
Two lines of CT,
RT, surgery
1 None PD
6 64 M III (T3N0M0) Primary tumor Two lines of
CT, RT
0 None SD (16+ months)
7 49 M Unknown Skull base, lung,
lymph nodes,
orbital cavity
Three lines of CT,
RT, surgery
1 Orbital edema and
visual field defects
PR (5 months)
8 40 M Unknown Primary tumor,
skull base
Three lines of
CT, RT
0 None MR (12 months)
9 66 M IV (TXN2M1) Primary tumor,
neck
Three lines of CT 0 None PD
10 50 M IV (T4N2M0) Liver Two lines of CT 1 None PD
11 46 M II (T2N1M0) Lung, lymph
nodes, liver
Two lines of CT,
RT, surgery
1 None PD
NPC, nasopharyngeal carcinoma; EBV, Epstein–Barr virus; CTL, cytotoxic T lymphocyte; ECOG PS, Eastern Cooperative Oncology Group performance status;
F, female; M, male; RT, radiotherapy; ChT, chemotherapy; SD, stable disease; M, male; PR, partial response; PD, progressive disease; MR, minor response; UPN,
unique patient number.
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CTL infusion, all patients showed lymphopenia (£0.2 · 109/l)
and lymphocyte counts returned to baseline levels only after
administration of the second EBV-CTL infusion.
To assess the immune response to EBV antigens, IFN-c
ELISPOT assays were carried out by stimulating PBMCs with
autologous LCLs or with an LMP2 peptide pool.
Lymphodepletion caused a decrease in the frequency of EBV-
specific T cells, as indicated by a persistent lower virus-specific
T-cell frequency also after the first CTL infusion (median and
range IFN-c spot-forming units/105 cells: 418, 19–541 versus
148, 11–397, respectively, P < 0.05) (Figure 2A). Only after the
second dose of EBV-specific CTLs, did the median immune
response to EBV increase again, returning to baseline levels or
even to higher levels in some patients, indicating expansion of
adoptively transferred T cells (Figure 2). In particular, patients
2 and 7, who achieved a partial clinical response, and patient 4,
who maintained prolonged stable disease, showed an increase
in the response to LMP2 antigen after the second CTL infusion
(Figure 2B).
To investigate whether the slow kinetics of lymphocyte
recovery after lymphodepleting treatment could be due to
a hampered secretion of cytokines that promote homeostatic
lymphocyte expansion in the lymphopenic host, we measured
plasma levels of IL-15 before lymphodepletion, before CTL
infusion and 1 week after CTL administration. We observed
a significant increase (P < 0.05) in the plasma levels of IL-15 at
the time of the CTL infusion, which returned to baseline within
1 week (Figure 3). Therefore, failure to show a prompt
lymphoid expansion after CTL transfer does not seem to
depend on an altered cytokine milieu at the time of CTL
infusion.
clinical benefit of EBV-targeted autologous CTL
therapy
At the first evaluation, 4 weeks after the second CTL infusion,
two patients (patients 2 and 7) showed a partial response (PR)
defined according to RECIST, which lasted 8 and 5 months,
respectively; one patient (patient 8) showed a minor response
(i.e. 20% reduction in the size of target lesions), lasting 12
months. Three patients had stable disease, lasting a median of 8
months (range 4–22 months). The patients who showed clinical
responses received maintenance doses of EBV-CTLs (median
number of additional infusions: 5, range 4–8). Five patients had
progressive disease; 10 patients died at a median of 14.5 months
(range 5–23 months) after CTL infusion, and 1 patient is alive
with active disease at 38 months from CTL treatment. The
outcome of each patient is summarized in Table 1.
Plasma EBV DNA is a marker of disease in NPC patients.
Therefore, we evaluated clinical response also on the basis of
this parameter. Before lymphodepletion, the patients showed
a median plasma EBV DNA load of 1360 copies/ml (range 0–52
980), which slightly increased to 1740 copies/ml (range 0–47
240) before CTL administration. After T-cell therapy, an overall
1-log decrease was observed (median of 154 copies/ml, range
0–23 680), reaching a 2-log reduction in the patients showing
clinical responses (Figure 4). Further evaluations showed a new
increase in the median levels of plasma EBV DNA,
corresponding to disease progression (Figure 4). The patients
that had PRs or long duration of stabilized disease, and received
additional CTL doses, showed fluctuations in EBV DNA levels
according to the administration of maintenance EBV-CTL
infusions.
discussion
We previously documented the feasibility of generating in vitro
autologous EBV-specific CTLs from NPC patients, which
possessed in vitro antitumor activity and were able to induce
disease control once administered in vivo [18]. In particular,
repeated infusions of up to 1 · 106 CTLs/kg body weight
provided a clinical benefit in 6 of 10 heavily pretreated patients.
In an attempt to improve the efficacy of our adoptive EBV-
specific cell therapy, we chose to modify our approach
according to recent reports that suggested a role for a high cell
dose preceded by lymphodepletion in T-cell therapy for solid
tumors [23]. We reasoned that, in the context of a solid tumor
such as EBV-related NPC with large tumor burden, a higher
number of EBV-specific CTLs would enhance clinical
responses, as observed in melanoma patients treated with
tumor-infiltrating lymphocytes [21]. Moreover, in the latter
setting, delivery of lymphoablative chemotherapy, consisting of
fludarabine and cyclophosphamide, before T-cell
administration, favored the spontaneous expansion of infused
T cells, contributing to CTL persistence [24]. Based on this
study and others, it has been suggested that lymphodepleting
chemotherapy could play a role in favorably modifying the
tumor microenvironment, by reducing levels of both regulatory
T cells and regulatory cytokines, which suppress T-cell effector
function and, consequently, tumor surveillance [25–28].
Despite having employed both a lymphodepleting regimen
and higher doses of EBV-specific autologous CTLs, the results
obtained in the present cohort are substantially comparable
with our previous experience, with clinical benefit observed in
about half the study population. These data indicate that either
the two variables did not provide additional benefit or had
competing effects. We favor the hypothesis that the
lymphodepleting chemotherapy counteracted the possible
benefits derived from a higher CTL dose. It is possible that
Figure 1. Kinetics of lymphocyte absolute numbers in treated patients.
Lymphocyte counts per milliliter in the 11 patients at different times
before and after lymphodepleting therapy and EBV-specific CTL infusion
are shown. The median value for each time point is reported as
a continuous blue line. EBV, Epstein–Barr virus; CTL, cytotoxic T
lymphocyte.
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during the 5-week interval before resolution of peripheral
lymphopenia, the new environment was not able to fully
support expansion and activation of transferred CTLs. In
addition, with regard to its impact on T-regulatory
lymphocytes, the profound and prolonged lymphopenia may
have also depleted factors able to promote T-cell effector
function or expansion. Indeed, the transient IL-15 production
peak observed after lymphodepletion might not have been
adequate to favor cell expansion in the absence of helper T cells
producing other homeostatic factors. In support of this
hypothesis, studies using highly selected tumor-reactive CD8+
clones, administered following lymphodepletion, did not
provide evidence of tumor regression, suggesting that the
presence of CD4+ cells is necessary to mediate an antitumor
response [23, 29]. In line with these observations, it has been
recently reported that autologous antigen-specific CD4+ cells,
given in the absence of lymphodepletion, persisted in vivo for
at least 3 months and induced a long lasting complete
remission in a patient with metastatic and refractory
melanoma [30]. This report suggests that CD4+ T cells play
a central role in antitumor immunity and supports the
hypothesis that, at least in the NPC setting, an environment
with a subverted cytokine profile, as observed following
lymphodepletion, may impair antitumor surveillance by
hampering CTL function. Whether a more intensive,
myeloablative, approach [31] may provide a more favorable
environment for CTL expansion remains to be tested in
a cohort of less compromised patients at an earlier stage of
disease. Alternatively, the use of a less toxic agent, such as the
CD45 lymphodepleting antibody, may be a better choice in
NPC patients. Louis et al. [32] reported an increase in
peripheral blood frequency of EBV-specific T cells after CTL
infusion preceded by CD45 antibody treatment, compared
with their previous experience without lymphodepletion,
although the clinical effects did not seem to be strikingly
improved. The lymphodepleting effect of the mAb treatment
was of shorter duration than our chemotherapy-based
regimen, and the more prolonged lymphopenia we observed
Figure 2. Immune response to EBV-LCL and to LMP2 antigen in treated patients. Data on the frequency of IFN-c-secreting lymphocytes, measured in
patient PBMCs obtained before (white bars), 2 weeks (gray bars), and 8 weeks (black bars) after CTL therapy, in response to EBV-LCL (panel A) and EBV-
LMP2 protein peptide mix (panel B) are reported. On the horizontal axis, the 11 consecutive patients are reported. IFN-c-secreting cells are represented as
number of spots/105 PBMCs (mean spots of triplicate experiments). EBV, Epstein–Barr virus; LCL, lymphoblastoid cell line; LMP2, latent membrane
proteins 2; IFN, interferon; PBMC, peripheral blood mononuclear cells; CTL, cytotoxic T lymphocyte.
Figure 3. Levels of IL-15 in the plasma of patients before and after
lymphodepletion. Data on the plasma levels of IL-15, measured in patient
samples obtained before lymphoablation (pre-LA), before CTL infusion
(pre-CTL), and 1 week after CTL infusion (post-CTL) are reported. IL-15
concentrations were quantified by ELISA using mAb pairs (Pierce
Endogen, Rockford, IL). Plates were coated with purified antibodies at the
appropriate concentrations. Standard curves were prepared with
recombinant human cytokine (Pierce Endogen). Biotin-labeled antibodies
(Pierce Endogen) were added and HRP-conjugated streptavidin (Pierce
Endogen) was used to develop the reactions. Plates were read at 450 nm
(Titertek Plus MS 212M). IL, interleukin; CTL, cytotoxic T lymphocyte;
ELISA, enzyme-linked immunosorbent assay; HRP, horseradish
peroxidase.
Figure 4. Kinetics of EBV DNA levels in treated patients. Data on EBV
DNA levels in the plasma of patients before lymphoablation (pre-LA),
immediately before (pre-CTL), and 1 week (+1 week) and 2–6 months
(+8–24 weeks) after CTL infusion are reported. EBV DNA analysis was
carried out according to a previously described method [22]. EBV,
Epstein–Barr virus; CTL, cytotoxic T lymphocyte.
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may account for failure to detect early T-cell expansion after
CTL therapy.
The kinetics of EBV DNA load in our patients indicates
that also in the setting of cell therapy, this parameter
correlates with tumor burden [22] and may be employed to
monitor response in the course of treatment and follow-up.
Our study confirms that EBV-specific CTL therapy is
associated with antitumor activity in patients with advanced
NPC. The use of lymphodepleting chemotherapy before T-
cell administration did not improve clinical results but
possibly dampened preexisting EBV-specific T cells.
Importantly, compared with our previous experience, we
have shown that CTLs can be given at higher doses without
additional toxicity. Thus, the priority for future studies will
be to ameliorate the quality of the cell product rather than
act on the tumor environment.
In this perspective, efforts are being made toward
augmenting the pool of T cells specific for the subdominant
antigens expressed on EBV latency II tumor cells within the
infused product, with the aim of increasing T-cell therapy
efficacy. In detail, the subdominant component of EBV-
specific immune response directed toward LMPs LMP1 and
LMP2 has been shown to expand, by stimulation with
dendritic cells or EBV-LCL genetically modified to express
the antigens [33–35]. In a pilot study enrolling EBV-positive
Hodgkin or non-Hodgkin lymphoma, five of six patients
with active relapsed disease showed a tumor response after
infusion of autologous LMP2-specific CTLs [36].
Based on these preliminary data, and on the results of the
immunological monitoring of the treated patients in our
cohorts, which confirm a correlation between the emergence
of LMP2-specific T cells and a clinical response, we are now
working on methods to obtain enrichment of CTLs specific
for the subdominant antigen EBV-LMP2 and other antigens
potentially present on NPC tumor cells, such as LMP1 and
EBNA1. These cell products will likely exert an optimal
antitumor effect if employed in earlier phases of the disease.
In particular, we intend to conduct future studies in patients
relapsing, or not achieving remission, after conventional
first-line treatment. In this setting, we would use CTLs as
a consolidation treatment after achieving response to
second-line therapy. Likewise, we could consider T-cell
therapy for consolidating maximal response in patients
treated for metastatic disease.
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